CervoMed Inc
NASDAQ:CRVO
| Market Cap (Intraday) | 61.71M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $6.59 |
| 50-Day MA | $7.74 |
| 200-Day MA | $7.68 |
CervoMed Inc Stock, NASDAQ:CRVO
20 Park Plaza, Suite 424, Boston, Massachusetts 02216
United States of America
Phone: +1.617.744.4400
Number of Employees: 15
Description
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.